Latest Update: Impact of current COVID-19 situation has been considered in this report while making the analysis.
Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Market by Type (CEL-1000, D-3252, FDX-000, INO-4500, LCA-60, Others), By Application (Hospital, Clinic, Research Center) and Region (North America, Latin America, Europe, Asia Pacific and Middle East & Africa), Forecast From 2022 To 2030-report

Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Market by Type (CEL-1000, D-3252, FDX-000, INO-4500, LCA-60, Others), By Application (Hospital, Clinic, Research Center) and Region (North America, Latin America, Europe, Asia Pacific and Middle East & Africa), Forecast From 2022 To 2030

Report ID: 275944 4200 Pharma & Healthcare 377 235 Pages 4.6 (42)
                                          

Market Overview:


The global severe acute respiratory syndrome (SARS) therapeutics market is expected to register a CAGR of XX% during the forecast period 2018-2030. The market growth can be attributed to the increasing incidence of SARS, rising awareness about SARS and its treatment, and technological advancements in the field of SARS therapeutics. However, factors such as high cost of treatment and lack of reimbursement policies are likely to restrain the growth of this market during the forecast period. Based on type, the global severe acute respiratory syndrome (SARS) therapeutics market is segmented into CEL-1000, D-3252, FDX-000, INO-4500 LCA-60 Others. Based on application, it is segmented into hospital clinic research center. Geographically it has been analyzed across North America Latin America Europe Asia Pacific Middle East & Africa with further analysis done for key countries in each region.


Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Industry Outlook


Product Definition:


A severe, highly contagious respiratory illness caused by a previously unknown virus. Symptoms include fever, coughing, and difficulty breathing. SARS Therapeutics is important because it can help to treat the symptoms of this illness.


CEL-1000:


Celgene Corporation (U.S.), a major market player, has developed CEL-1000 in collaboration with BioCryst Pharmaceuticals for the treatment of SARS-CoV-2 infection. The drug is currently under phase III clinical trials and expected to be commercialized by 2017.


D-3252:


D-3252 is a selective inhibitor of voltage-gated L type calcium channels. It has potent anti-inflammatory and immunosuppressive properties, which may be useful in the treatment of SARS. Currently, it is under clinical investigation for this purpose and has been found to have nootropic effects when used in high doses over an extended period.


Application Insights:


Based on application, the global severe acute respiratory syndrome therapeutics market is segmented into hospital, clinic and research center. The hospital segment dominated the overall market in terms of revenue in 2017 owing to a large patient base with SARS-CoV-2 infection and increasing prevalence of severe SARS-CoV disease. In addition, this segment is expected to maintain its dominance over the forecast period due to ongoing clinical trials for potential new therapies.


The Clinic/research center segment is anticipated to witness lucrative growth during the forecast period due to increased R&D initiatives by public and private organizations at global level coupled with growing awareness about Severe Acute Respiratory Syndrome (SARS). For instance, Centers for Disease Control & Prevention (CDC) has recommended that people be tested frequently if they have been in contact with a person diagnosed with SARS-CoV since it can spread easily among humans.


Regional Analysis:


North America dominated the global market in 2017 owing to the presence of a substantial number of players, high research activities, and favorable government initiatives. The region is expected to maintain its dominance throughout the forecast period due to factors such as increasing prevalence of SARS-CoV infection and rising healthcare expenditure. Asia Pacific is anticipated to witness lucrative growth over the forecast period owing to increasing awareness about early diagnosis coupled with growing R&D activities by various companies for developing novel therapeutics for tackling this pandemic situation efficiently. Moreover, low manufacturing cost in countries like China & India coupled with easy availability of raw materials will drive regional growth further. In addition, increase in foreign investments are also contributing towards market development across emerging economies globally which include Indonesia & Malaysia among others (Table 1).


Growth Factors:


  • Increasing incidence of respiratory diseases: The global incidence of respiratory diseases is increasing due to the changing lifestyle and environmental conditions. This is expected to drive the demand for SARS therapeutics products in the coming years.
  • Growing awareness about SARS: There is a growing awareness among people about SARS and its treatment options. This is likely to boost the demand for SARS therapeutics products in the near future.
  • Technological advancements: The technological advancements in the field of respiratory disease treatments are expected to fuel the growth of the global SARS therapeutics market in future years.
  • Rising healthcare expenditure: The rising healthcare expenditure by governments and private players is anticipated to create lucrative opportunities for players operating in this market during forecast period 2017-2025 .

Scope Of The Report

Report Attributes

Report Details

Report Title

Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Research Report

By Type

CEL-1000, D-3252, FDX-000, INO-4500, LCA-60, Others

By Application

Hospital, Clinic, Research Center

By Companies

CEL-SCI Corporation, GeneCure LLC, Humabs BioMed SA, Inovio Pharmaceuticals, Inc., Nanotherapeutics, Inc., Novavax, Inc., Phelix Therapeutics, LLC, Protein Sciences Corporation

Regions Covered

North America, Europe, APAC, Latin America, MEA

Base Year

2021

Historical Year

2019 to 2020 (Data from 2010 can be provided as per availability)

Forecast Year

2030

Number of Pages

235

Number of Tables & Figures

165

Customization Available

Yes, the report can be customized as per your need.


Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Report Segments:

The global Severe Acute Respiratory Syndrome (SARS) Therapeutics market is segmented on the basis of:

Types

CEL-1000, D-3252, FDX-000, INO-4500, LCA-60, Others

The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.

Applications

Hospital, Clinic, Research Center

The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.

Some of the companies that are profiled in this report are:

  1. CEL-SCI Corporation
  2. GeneCure LLC
  3. Humabs BioMed SA
  4. Inovio Pharmaceuticals, Inc.
  5. Nanotherapeutics, Inc.
  6. Novavax, Inc.
  7. Phelix Therapeutics, LLC
  8. Protein Sciences Corporation

Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Overview


Highlights of The Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Report:

  1. The market structure and projections for the coming years.
  2. Drivers, restraints, opportunities, and current trends of market.
  3. Historical data and forecast.
  4. Estimations for the forecast period 2030.
  5. Developments and trends in the market.
  6. By Type:

    1. CEL-1000
    2. D-3252
    3. FDX-000
    4. INO-4500
    5. LCA-60
    6. Others
  1. By Application:

    1. Hospital
    2. Clinic
    3. Research Center
  1. Market scenario by region, sub-region, and country.
  2. Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
  3. Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
  4. Government Policies, Macro & Micro economic factors are also included in the report.

We have studied the Severe Acute Respiratory Syndrome (SARS) Therapeutics Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.

Regional Analysis

  • North America
  • Europe
  • Asia Pacific
  • Middle East & Africa
  • Latin America

Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.

The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.

How you may use our products:

  • Correctly Positioning New Products
  • Market Entry Strategies
  • Business Expansion Strategies
  • Consumer Insights
  • Understanding Competition Scenario
  • Product & Brand Management
  • Channel & Customer Management
  • Identifying Appropriate Advertising Appeals

Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Statistics

8 Reasons to Buy This Report

  1. Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
  2. Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
  3. Implemented Robust Methodology to Prepare the Report
  4. Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
  5. Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
  6. Provides Information About the Top-winning Strategies Implemented by Industry Players.
  7. In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
  8. Customization of the Report Available

Frequently Asked Questions?


SARS therapeutics are medications used to treat SARS. These medications can help reduce the symptoms of SARS, such as fever, cough, and shortness of breath.

Some of the major companies in the severe acute respiratory syndrome (sars) therapeutics market are CEL-SCI Corporation, GeneCure LLC, Humabs BioMed SA, Inovio Pharmaceuticals, Inc., Nanotherapeutics, Inc., Novavax, Inc., Phelix Therapeutics, LLC, Protein Sciences Corporation.

                                            
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Overview    4.1 Introduction       4.1.1 Market Taxonomy       4.1.2 Market Definition       4.1.3 Macro-Economic Factors Impacting the Market Growth    4.2 Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Dynamics       4.2.1 Market Drivers       4.2.2 Market Restraints       4.2.3 Market Opportunity    4.3 Severe Acute Respiratory Syndrome (SARS) Therapeutics Market - Supply Chain Analysis       4.3.1 List of Key Suppliers       4.3.2 List of Key Distributors       4.3.3 List of Key Consumers    4.4 Key Forces Shaping the Severe Acute Respiratory Syndrome (SARS) Therapeutics Market       4.4.1 Bargaining Power of Suppliers       4.4.2 Bargaining Power of Buyers       4.4.3 Threat of Substitution       4.4.4 Threat of New Entrants       4.4.5 Competitive Rivalry    4.5 Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size & Forecast, 2018-2028       4.5.1 Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size and Y-o-Y Growth       4.5.2 Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Absolute $ Opportunity

Chapter 5 Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Analysis and Forecast by Type
   5.1 Introduction
      5.1.1 Key Market Trends & Growth Opportunities by Type
      5.1.2 Basis Point Share (BPS) Analysis by Type
      5.1.3 Absolute $ Opportunity Assessment by Type
   5.2 Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size Forecast by Type
      5.2.1 CEL-1000
      5.2.2 D-3252
      5.2.3 FDX-000
      5.2.4 INO-4500
      5.2.5 LCA-60
      5.2.6 Others
   5.3 Market Attractiveness Analysis by Type

Chapter 6 Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Analysis and Forecast by Applications
   6.1 Introduction
      6.1.1 Key Market Trends & Growth Opportunities by Applications
      6.1.2 Basis Point Share (BPS) Analysis by Applications
      6.1.3 Absolute $ Opportunity Assessment by Applications
   6.2 Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size Forecast by Applications
      6.2.1 Hospital
      6.2.2 Clinic
      6.2.3 Research Center
   6.3 Market Attractiveness Analysis by Applications

Chapter 7 Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Analysis and Forecast by Region
   7.1 Introduction
      7.1.1 Key Market Trends & Growth Opportunities by Region
      7.1.2 Basis Point Share (BPS) Analysis by Region
      7.1.3 Absolute $ Opportunity Assessment by Region
   7.2 Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size Forecast by Region
      7.2.1 North America
      7.2.2 Europe
      7.2.3 Asia Pacific
      7.2.4 Latin America
      7.2.5 Middle East & Africa (MEA)
   7.3 Market Attractiveness Analysis by Region

Chapter 8 Coronavirus Disease (COVID-19) Impact 
   8.1 Introduction 
   8.2 Current & Future Impact Analysis 
   8.3 Economic Impact Analysis 
   8.4 Government Policies 
   8.5 Investment Scenario

Chapter 9 North America Severe Acute Respiratory Syndrome (SARS) Therapeutics Analysis and Forecast
   9.1 Introduction
   9.2 North America Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size Forecast by Country
      9.2.1 U.S.
      9.2.2 Canada
   9.3 Basis Point Share (BPS) Analysis by Country
   9.4 Absolute $ Opportunity Assessment by Country
   9.5 Market Attractiveness Analysis by Country
   9.6 North America Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size Forecast by Type
      9.6.1 CEL-1000
      9.6.2 D-3252
      9.6.3 FDX-000
      9.6.4 INO-4500
      9.6.5 LCA-60
      9.6.6 Others
   9.7 Basis Point Share (BPS) Analysis by Type 
   9.8 Absolute $ Opportunity Assessment by Type 
   9.9 Market Attractiveness Analysis by Type
   9.10 North America Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size Forecast by Applications
      9.10.1 Hospital
      9.10.2 Clinic
      9.10.3 Research Center
   9.11 Basis Point Share (BPS) Analysis by Applications 
   9.12 Absolute $ Opportunity Assessment by Applications 
   9.13 Market Attractiveness Analysis by Applications

Chapter 10 Europe Severe Acute Respiratory Syndrome (SARS) Therapeutics Analysis and Forecast
   10.1 Introduction
   10.2 Europe Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size Forecast by Country
      10.2.1 Germany
      10.2.2 France
      10.2.3 Italy
      10.2.4 U.K.
      10.2.5 Spain
      10.2.6 Russia
      10.2.7 Rest of Europe
   10.3 Basis Point Share (BPS) Analysis by Country
   10.4 Absolute $ Opportunity Assessment by Country
   10.5 Market Attractiveness Analysis by Country
   10.6 Europe Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size Forecast by Type
      10.6.1 CEL-1000
      10.6.2 D-3252
      10.6.3 FDX-000
      10.6.4 INO-4500
      10.6.5 LCA-60
      10.6.6 Others
   10.7 Basis Point Share (BPS) Analysis by Type 
   10.8 Absolute $ Opportunity Assessment by Type 
   10.9 Market Attractiveness Analysis by Type
   10.10 Europe Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size Forecast by Applications
      10.10.1 Hospital
      10.10.2 Clinic
      10.10.3 Research Center
   10.11 Basis Point Share (BPS) Analysis by Applications 
   10.12 Absolute $ Opportunity Assessment by Applications 
   10.13 Market Attractiveness Analysis by Applications

Chapter 11 Asia Pacific Severe Acute Respiratory Syndrome (SARS) Therapeutics Analysis and Forecast
   11.1 Introduction
   11.2 Asia Pacific Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size Forecast by Country
      11.2.1 China
      11.2.2 Japan
      11.2.3 South Korea
      11.2.4 India
      11.2.5 Australia
      11.2.6 South East Asia (SEA)
      11.2.7 Rest of Asia Pacific (APAC)
   11.3 Basis Point Share (BPS) Analysis by Country
   11.4 Absolute $ Opportunity Assessment by Country
   11.5 Market Attractiveness Analysis by Country
   11.6 Asia Pacific Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size Forecast by Type
      11.6.1 CEL-1000
      11.6.2 D-3252
      11.6.3 FDX-000
      11.6.4 INO-4500
      11.6.5 LCA-60
      11.6.6 Others
   11.7 Basis Point Share (BPS) Analysis by Type 
   11.8 Absolute $ Opportunity Assessment by Type 
   11.9 Market Attractiveness Analysis by Type
   11.10 Asia Pacific Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size Forecast by Applications
      11.10.1 Hospital
      11.10.2 Clinic
      11.10.3 Research Center
   11.11 Basis Point Share (BPS) Analysis by Applications 
   11.12 Absolute $ Opportunity Assessment by Applications 
   11.13 Market Attractiveness Analysis by Applications

Chapter 12 Latin America Severe Acute Respiratory Syndrome (SARS) Therapeutics Analysis and Forecast
   12.1 Introduction
   12.2 Latin America Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size Forecast by Country
      12.2.1 Brazil
      12.2.2 Mexico
      12.2.3 Rest of Latin America (LATAM)
   12.3 Basis Point Share (BPS) Analysis by Country
   12.4 Absolute $ Opportunity Assessment by Country
   12.5 Market Attractiveness Analysis by Country
   12.6 Latin America Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size Forecast by Type
      12.6.1 CEL-1000
      12.6.2 D-3252
      12.6.3 FDX-000
      12.6.4 INO-4500
      12.6.5 LCA-60
      12.6.6 Others
   12.7 Basis Point Share (BPS) Analysis by Type 
   12.8 Absolute $ Opportunity Assessment by Type 
   12.9 Market Attractiveness Analysis by Type
   12.10 Latin America Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size Forecast by Applications
      12.10.1 Hospital
      12.10.2 Clinic
      12.10.3 Research Center
   12.11 Basis Point Share (BPS) Analysis by Applications 
   12.12 Absolute $ Opportunity Assessment by Applications 
   12.13 Market Attractiveness Analysis by Applications

Chapter 13 Middle East & Africa (MEA) Severe Acute Respiratory Syndrome (SARS) Therapeutics Analysis and Forecast
   13.1 Introduction
   13.2 Middle East & Africa (MEA) Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size Forecast by Country
      13.2.1 Saudi Arabia
      13.2.2 South Africa
      13.2.3 UAE
      13.2.4 Rest of Middle East & Africa (MEA)
   13.3 Basis Point Share (BPS) Analysis by Country
   13.4 Absolute $ Opportunity Assessment by Country
   13.5 Market Attractiveness Analysis by Country
   13.6 Middle East & Africa (MEA) Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size Forecast by Type
      13.6.1 CEL-1000
      13.6.2 D-3252
      13.6.3 FDX-000
      13.6.4 INO-4500
      13.6.5 LCA-60
      13.6.6 Others
   13.7 Basis Point Share (BPS) Analysis by Type 
   13.8 Absolute $ Opportunity Assessment by Type 
   13.9 Market Attractiveness Analysis by Type
   13.10 Middle East & Africa (MEA) Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size Forecast by Applications
      13.10.1 Hospital
      13.10.2 Clinic
      13.10.3 Research Center
   13.11 Basis Point Share (BPS) Analysis by Applications 
   13.12 Absolute $ Opportunity Assessment by Applications 
   13.13 Market Attractiveness Analysis by Applications

Chapter 14 Competition Landscape 
   14.1 Severe Acute Respiratory Syndrome (SARS) Therapeutics Market: Competitive Dashboard
   14.2 Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Market: Market Share Analysis, 2019
   14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy) 
      14.3.1 CEL-SCI Corporation
      14.3.2 GeneCure LLC
      14.3.3 Humabs BioMed SA
      14.3.4 Inovio Pharmaceuticals, Inc.
      14.3.5 Nanotherapeutics, Inc.
      14.3.6 Novavax, Inc.
      14.3.7 Phelix Therapeutics, LLC
      14.3.8 Protein Sciences Corporation

Our Trusted Clients

Contact Us